Compare EVEX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | DBVT |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.2M | 948.8M |
| IPO Year | 2020 | 2014 |
| Metric | EVEX | DBVT |
|---|---|---|
| Price | $2.48 | $14.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.88 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 931.0K | 341.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $11,676.47 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $2.10 | $8.80 |
| 52 Week High | $5.16 | $26.19 |
| Indicator | EVEX | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 47.20 |
| Support Level | $2.26 | $12.75 |
| Resistance Level | $2.56 | $14.68 |
| Average True Range (ATR) | 0.16 | 0.69 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 4.26 | 57.45 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.